Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Research & Development (2016 - 2023)

Historic Research & Development for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $1.2 million.

  • RedHill Biopharma's Research & Development fell 1528.53% to $1.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $5.1 million, marking a year-over-year decrease of 6870.53%. This contributed to the annual value of $1.6 million for FY2024, which is 5498.87% down from last year.
  • Latest data reveals that RedHill Biopharma reported Research & Development of $1.2 million as of Q2 2023, which was down 1528.53% from $1.1 million recorded in Q1 2023.
  • Over the past 5 years, RedHill Biopharma's Research & Development peaked at $10.3 million during Q2 2021, and registered a low of $1.1 million during Q1 2023.
  • In the last 5 years, RedHill Biopharma's Research & Development had a median value of $3.1 million in 2020 and averaged $4.1 million.
  • In the last 5 years, RedHill Biopharma's Research & Development surged by 22134.41% in 2021 and then plummeted by 8574.75% in 2022.
  • RedHill Biopharma's Research & Development (Quarter) stood at $2.3 million in 2019, then surged by 171.92% to $6.2 million in 2020, then fell by 5.19% to $5.9 million in 2021, then plummeted by 80.69% to $1.1 million in 2022, then rose by 10.06% to $1.2 million in 2023.
  • Its Research & Development was $1.2 million in Q2 2023, compared to $1.1 million in Q1 2023 and $1.1 million in Q4 2022.